Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Prostate cancer, drawn from the whole corpus: 363 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Overdiagnosis vs. underdiagnosis in screening.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Neuroendocrine transformation.
Ac-225 supply.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Screening trade-off: PSA reduces mortality by ~20% but overdiagnoses; MRI-first and risk-adapted intervals are only partly adopted.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Neuroendocrine / lineage-plastic transformation in ~15-20% of late mCRPC has no targeted therapy; DLL3 and B7-H3 agents are being borrowed from SCLC.
Nothing recorded yet.
Also on OnCo: Targets · KRAS roadmap.
AR-V7 and N-terminal-domain resistance: masofaniten failed; AR degraders remain preclinical/early.
Background: Castration-resistant prostate cancer (CRPC). Also on OnCo: Resistance atlas · Lines of therapy.
Radioligand sequencing and resistance: 10% PSMA-negative disease, heterogeneity, and no proven therapy after 177Lu failure outside trials; Ac-225 supply is the constraint.
Background: Castration-resistant prostate cancer (CRPC). Also on OnCo: Resistance atlas · Lines of therapy.
Overall survival has been hard to show for PSMA radioligands beyond VISION (SPLASH, PSMAfore, TheraP confounded by crossover).
Immunotherapy: checkpoint inhibitors fail in unselected disease; engagers bring cytokine release and need outpatient models.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Equity: Black men have ~70% higher incidence and double the mortality yet are under-enrolled in trials; earlier, risk-adapted screening is the lever.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Bone health, cardiovascular risk, and cognitive effects of long-term ADT in men living a decade or more.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 99 changes by month →When this page itself was last checked or edited.
PSMA+ metastatic hormone-sensitive prostate cancer with ARPI (PSMAddition)
PTEN-deficient metastatic prostate cancer with abiraterone (CAPItello-281)
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Pylarify TruVu formulation
PTEN-deficient metastatic prostate cancer with abiraterone